Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review

被引:0
作者
Ghader Mohammadnezhad
Behniya Azadmehr
Mehdi Mirheidari
Nazila Yousefi
机构
[1] Shahid Beheshti University of Medical Sciences,Student Research Committee, School of Pharmacy
[2] Shahid Beheshti University of Medical Sciences,Department of Pharmacoeconomics and Pharma Management, School of Pharmacy
来源
Cost Effectiveness and Resource Allocation | / 20卷
关键词
Dapagliflozin; SGLT-2 inhibitors; Economic evaluation; Cost-effectiveness analysis; Heart failure;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 143 条
[21]  
Hernandez AF(2020)Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China ESC Hear Fail 32 890-44
[22]  
Chioncel O(2021)Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia Expert Rev Pharmacoecon Outcomes Res 22 37-undefined
[23]  
Lainscak M(2021)Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction Int J Cardiol undefined undefined-undefined
[24]  
Seferovic PM(2021)Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction JAMA Cardiol undefined undefined-undefined
[25]  
Anker SD(2019)Evaluating cost-effectiveness models for pharmacologic interventions in adults with heart failure: a systematic literature review Pharmacoeconomics undefined undefined-undefined
[26]  
Crespo-Leiro MG(2017)2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Circulation undefined undefined-undefined
[27]  
Harjola VP(2020)Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom Diabetes Obes Metab undefined undefined-undefined
[28]  
Murphy SP(2016)Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in greece Clin Drug Investig undefined undefined-undefined
[29]  
Ibrahim NE(2015)The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus Diabet Med undefined undefined-undefined
[30]  
Januzzi JL(2022)Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review Eur J Health Econ undefined undefined-undefined